Skip to content

ANIX

Anixa Biosciences Inc (ANIX

NASDAQ · Healthcare · Biotechnology · US

$2.61
−2.25%
Ask drillr
  • Sep 29, 2026, 23:59 UTC

    Anixa Biosciences is developing a breast cancer vaccine, currently about one-third of the way through human testing, designed to prevent recurrence and potentially the disease itself.

    Source:
  • Sep 21, 2026, 12:45 UTC

    Anixa Biosciences received an Australian patent for its breast cancer vaccine.

  • Jun 29, 2026, 12:45 UTC

    Anixa Biosciences was granted a Korean patent for its breast cancer vaccine by the Korean Ministry of Intellectual Property, extending protection through 2040.

  • Jun 1, 2026, 13:00 UTC

    Anixa Biosciences received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its ovarian cancer vaccine technology.